TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14503550
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of corticosteroids and cytotoxic medications
Study: 8672151
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (chemotherapy and radiotherapy followed by surgery)
Study: 1925820
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nifedipine and Captopril)
Study: 1925820
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) and Captopril (25 mg)
Study: 6388722
Drug: BICAP bipolar
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BICAP bipolar electrocoagulation treatment
Study: 30952032
Drug: CHORDATA® method
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHORDATA® method (body suspension and pendulum exercises)
Study: 26871851
Drug: Human urinary
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human urinary kallidinogenase for 7 days, followed by maintenance therapy of pancreatic kallikrein for 6 months
Study: 25144133
Drug: 6 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg·kg of caffeine (CAF)
Study: 22331946
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (WP) 80 mg/m² for 12 weeks followed by FEC (fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²) every 3 weeks for four cycles
Study: 22331946
Drug: Docetaxel (XT)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (XT) 75 mg/m² on day 1 and capecitabine (1,500 mg/m² on days 1 through 14) every 3 weeks for four cycles followed by FEC for four cycles
Study: 22331946
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (WP)
Study: 17959981
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 100 mg
Study: 17321219
Drug: Randomized Play-the-Winner
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized Play-the-Winner (RPW) treatment allocation
Study: 14722890
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of Edmonston-Zagreb measles vaccine (10^3.6 pfu/dose)
Study: 14722890
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Edmonston-Zagreb measles vaccine (10^4.27 pfu/dose)
Study: 14722890
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of Edmonston-Zagreb measles vaccine
Study: 14722890
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of Edmonston-Zagreb measles vaccine
Study: 11288792
Drug: EMD +
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD + AB (Enamel Matrix Proteins + Antibiotics)
Study: 3521856
Drug: Desoximetasone gel
Normalized name: Desoximetasone Gel
DrugBank: Desoximetasone (DB00547)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desoximetasone gel 0.05%
Study: 3521856
Drug: Fluocinonide gel
Normalized name: Fluocinonide Gel
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide gel 0.05%
Study: 28241237
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (dose adjusted to maintain normal testosterone levels for young men)
Study: 25853877
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (25 g/d for the first 5 days followed by 5 g/d for 8 weeks)
Study: 24043457
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene
Study: 24043457
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel
Study: 19059933
Drug: Low-dose cidofovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cidofovir (0.5 mg/kg) every 2 weeks for a total of six doses
Study: 19059933
Drug: Non-cidofovir treatment
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-cidofovir treatment (control group)
Study: 19059933
Drug: Low-dose cidofovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cidofovir
Study: 9612115
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (3 times 1 film-coated tablet daily for 24 weeks)
Study: 9612115
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times 1 film-coated tablet daily for 24 weeks)
Study: 2734718
Drug: Theophylline (Planphylline)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (Planphylline) 10 mg/kg/day in two doses at 8.30 a.m. and 8.30 p.m.
Study: 31077596
Drug: Cat-PAD (peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat-PAD (peptide immunotherapy)
Study: 23218193
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (≥ 28 cDDDs)
Study: 23218193
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (cDDDs 28 to 90)
Study: 23218193
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (cDDDs 91 to 365)
Study: 23218193
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (cDDDs > 365)
Study: 19333948
Drug: Relaxin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin therapy (both doses)
Study: 11320044
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (12.5 mg/kg, every six hours for 14 days)
Study: 2959308
Drug: Oral terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine 120 mg (pretreatment)
Study: 2959308
Drug: Oral cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cimetidine 400 mg (pretreatment)
Study: 30040760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (general physical therapy)
Study: 26625516
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of Lisinopril and Amlodipine
Study: 18417083
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Study: 18417083
Drug: No Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Study: 12212127
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 20 ppm nitric oxide (NO) during the early phase of reperfusion
Study: 12212127
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nitric oxide inhalation)
Study: 9116275
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) maintenance therapy (5 to 10 mg/kg/d) after 32P treatment
Study: 9116275
Drug: 32P treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32P treatment alone
Study: 9116275
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) maintenance therapy
Study: 9116275
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) maintenance therapy in severe cases with rapid recurrence
Study: 7960627
Drug: Volumetric acquisitions
Normalized name: SETS,VOLUMETRIC,INTRAVENOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric acquisitions with intravenous gadolinium
Study: 7960627
Drug: Two-dimensional interleaved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dimensional interleaved gradient-recalled-echo pulse sequences with intravenous gadolinium
Study: 2884811
Drug: Dixyrazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine (50 mg/day)
Study: 31715274
Drug: Rapid responders
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid responders (≥80% decrease in level of AST after 8 weeks of treatment with predniso(lo)ne)
Study: 26669201
Drug: Red-hot needle
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Red-hot needle therapy combined with cupping
Study: 23123791
Drug: 12-week pragmatic
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week pragmatic exercise therapy intervention
Study: 14519140
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day vitamin C
Study: 14519140
Drug: 450 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day magnesium chelate
Study: 12651048
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone for 48 to 72 hours
Study: 9053533
Drug: Vancomycin (VCM)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VCM) in combination with beta-lactam antibiotics
Study: 9053533
Drug: Vancomycin (VCM)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VCM) alone or in combination with another drug
Study: 9053533
Drug: Vancomycin (VCM)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin (VCM) in combination with other antibiotics
Study: 2069371
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg) administered orally once daily for 5 days
Study: 2069371
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once daily for 5 days
Study: 20436517
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + filgrastim (r-metHuG-CSF)
Study: 20436517
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (Chemotherapy + filgrastim)
Study: 18360781
Drug: Standard BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BP treatment (MAP 110-130 mmHg)
Study: 8330599
Drug: i.m. buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. buprenorphine 0.3 mg
Study: 8330599
Drug: i.m. buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. buprenorphine 0.3 mg (prophylactic)
Study: 27060419
Drug: Short and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short and intensive speech therapy (6 hours over 3-4 days)
Study: 16216530
Drug: Sex hormones
Normalized name: GENITO URINARY SYSTEM AND SEX HORMONES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormones among HT users
Study: 9170894
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges, administered every 2 hours for the duration of cold symptoms
Study: 9170894
Drug: Placebo lozenges,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges, administered every 2 hours for the duration of cold symptoms
Study: 31221565
Drug: Topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac 0.3%
Study: 22117983
Drug: Wheat dextrin
Normalized name: wheat dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat dextrin (15 g/day)
Study: 9175240
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 g/day)
Study: 19213680
Drug: Dronedarone, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone, 400 mg twice a day
Study: 16838229
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg 2 times per day for 7 days)
Study: 16838229
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg 2 times per day for 10 days)
Study: 16838229
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg 4 times per day for 10 days)
Study: 9109584
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with headgear
Study: 9109584
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with modified bionator
Study: 3813141
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam premedication
Study: 3813141
Drug: Intramuscular diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diazepam premedication
Study: 24965823
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²) once weekly for 4 weeks
Study: 20179981
Drug: Avocado soybean
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado soybean unsaponifiable (Piascledine) 300 mg once daily
Study: 20179981
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 400 mg three times daily
Study: 9857355
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 5, 10, 20 or 40 micrograms of a new hepatitis B vaccine
Study: 9857355
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20 micrograms of the vaccine
Study: 9857355
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 20 micrograms or 40 micrograms of the vaccine formulation
Study: 15100667
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (subcutaneous injections of a mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae vaccine; n=41)
Study: 11430712
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 6-11 microg/kg/d in the evening with GH 0.1 IU/kg/d sc at bedtime
Study: 11430712
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 6-11 microg/kg/d in the morning with GH 0.1 IU/kg/d sc at bedtime
Study: 29406821
Drug: Goiter dispersion
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goiter dispersion formula and antithyroid drugs (methimazole or propylthiouracil)
Study: 29406821
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug alone
Study: 28606450
Drug: Hourly recorded
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly recorded messages in a family member's voice during waking hours over 3 ICU days
Study: 28606450
Drug: Hourly recorded
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly recorded messages in a non-family voice during waking hours over 3 ICU days
Study: 1794297
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g orally daily for 6 months)
Study: 30635256
Drug: Fronto-temporal tDCS
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fronto-temporal tDCS (2-mA, twice-daily sessions for 5 days)
Study: 27534747
Drug: Dydrogesterone 40
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 40 mg per os, followed by 10 mg per os three times a day until twelve completed weeks of gestation or 1 week after the bleeding has stopped, whichever is longer.
Study: 19636975
Drug: Ambroxol (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (90 mg, three times per day for 3 months)
Study: 16923362
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ambroxol treatment)
Study: 16316362
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose (1 g in divided IV doses over 14 days)
Study: 16316362
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulfate, 325 mg orally thrice daily for 56 days)
Study: 16316362
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose (200 mg IV over two to five minutes)
Study: 9594486
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate inhaled twice daily
Study: 31574114
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion of 10 IU oxytocin
Study: 31574114
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection of 10 IU oxytocin
Study: 3161703
Drug: Diflunisal once
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal once daily (500 mg or 1000 mg)
Study: 3161703
Drug: Diflunisal twice
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal twice daily
Study: 20924215
Drug: Clevudine 30
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 30 mg daily
Study: 17650294
Drug: Hepimmune vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepimmune vaccine (four injections in 2 weeks intervals)
Study: 17650294
Drug: Standard HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HBV vaccine (HBVAXPRO)
Study: 12182370
Drug: Alcohol-based hand
Normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based hand gel with multifaceted quality improvement (QI) interventions
Study: 18171181
Drug: Alcohol-based hand
Normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based hand gel
Study: 12182370
Drug: Alcohol-based hand
Normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based hand gel with QI support
Study: 9476749
Drug: Late sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late sleep deprivation (LSD) twice weekly during week 1 and 2 followed by LSD once weekly during week 3 and 4
Study: 9476749
Drug: Late sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late sleep deprivation (LSD) once weekly
Study: 9476749
Drug: Late sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late sleep deprivation (LSD) twice weekly followed by once weekly
Study: 2146040
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on diuretic therapy
Study: 219471
Drug: Chlorthalidone (diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (diuretic therapy)
Study: 31907833
Drug: Sublingual trinitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual trinitroglycerin (TNG)
Study: 31907833
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (AD)
Study: 31915072
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h)
Study: 30731195
Drug: Nucleot(s)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleot(s)ide analogue therapy
Study: 26460293
Drug: Budesonide 160
Normalized name: BUDESONIDE 160/FORMOTER 4.5MCG 60D INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 160 μg (80 μg × 2 inhalations) twice daily via pMDI
Study: 23324079
Drug: Sorafenib in
Normalized name: Product containing sorafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib in combination with TACE
Study: 19803786
Drug: Citicoline (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1000 mg twice a day)
Study: 9177956
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus total sleep deprivation (TSD)
Study: 3304827
Drug: Multiload-250 (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiload-250 (ML)
Study: 25096315
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior group therapy for back pain (CBT-BP), six sessions.
Study: 25096315
Drug: Unspecific occupational
Normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unspecific occupational therapy sessions (control group).
Study: 20814330
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (6 mg/d, flexible dosing 3-12 mg/d)
Study: 15953743
Drug: Isotonic MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Isotonic MgSO4 (2.5 ml, 6.3%) + salbutamol (2.5 ml)
Study: 15953743
Drug: Saline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2.5 ml) + salbutamol (2.5 ml)